Companion Diagnostic to Help Development of Cancer Therapy

FISH-based companion diagnostic tests are designed to identify specific DNA sequences to help determine which patients are likely to benefit from a particular therapy. FISH technology can identify whether too many, or too few, copies of a particular gene are present in the body's cells, or whether certain genes have rearrangements that play an active role in disease progression. Cancer diagnostics is one of its fastest growing applications.

Abbott will develop a test based on its FISH technology, intended to identify deletions of the TP53 gene in cancer patients. The Abbott FISH assay will be evaluated in clinical trials to help identify patients more likely to respond favorably to Merck’s investigational cancer therapy.

Abbott Molecular is a leader in molecular diagnostics. The company analyses DNA and RNA at the molecular level. "Our goal through this collaboration, and others like it, is to ensure that the right medicine gets to the right patient," said Stafford O’Kelly, head of Abbott’s molecular diagnostics business. "As one of the early pioneers in companion diagnostics, we believe that linking genetic testing with drug development at the earliest stages can increase the effectiveness and predictability of medicines and help physicians make more informed treatment decisions."

Abbott's portfolio of companion diagnostic tests includes the PathVysion HER-2 DNA probe kit, which represents one of the first examples of innovations in the field of personalized medicine. The test is approved for use in selecting breast cancer patients for whom Herceptin (trastuzumab) therapy is being considered. In addition, Abbott's Vysis ALK Break Apart FISH probe kit was approved in 2011 for use in identifying non-small-cell lung cancer patients for Xalkori (crizotinib) treatment.

Related Links:
Abbott
Merck